Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01605253 · ClinicalTrials.gov registry record · Phase 4
Eszopiclone for the Treatment of Posttraumatic Stress Disorder
A Phase 4 study, sponsored by Rush University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 81
- Enrollment target
NCT01605253 is a Phase 4 study that has completed, run by Rush University Medical Center. The registered enrollment target is 81 participants.
The verdict
NCT01605253, a Phase 4 study, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 81 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if eszopiclone relative to placebo (sugar pill) is effective and tolerable for people with posttraumatic stress disorder (PTSD)-related sleep disturbance. The investigators will also examine the impact of treatment on sleep patterns, memory recall bias, and level of inflammatory markers (cytokines). The investigators predict eszopiclone will lead to greater improvement than placebo in measures of PTSD symptoms, memory recall bias, and level of inflammatory markers.
Interventions
- DRUG Placebo
- DRUG Eszopiclone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2012-03 |
| Est. Completion | 2015-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01605253
The ClinicalTrials.gov registry entry for NCT01605253 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01605253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01605253 about?
NCT01605253 is a clinical study titled "Eszopiclone for the Treatment of Posttraumatic Stress Disorder". The purpose of this study is to determine if eszopiclone relative to placebo (sugar pill) is effective and tolerable for people with posttraumatic stress disorder (PTSD)-related sleep disturbance. The investigators will also examine the impact of treatment on sleep patterns, memory recall bias, and ...
What is the current status of trial NCT01605253?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 81 participants. The study started on 2012-03. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01605253?
The interventions under investigation include: Placebo (DRUG), Eszopiclone (DRUG).
Who is sponsoring clinical trial NCT01605253?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.